Member Info for tqhussain

In the interims, it mentioned Glycotest is due to receive the last tranche from Fosun.

‘The bulk of the significant spend has already been deployed and becomes due for reimbursement by Fosun, under the existing agreement. In 2021, Fosun made a further payment on account of $1 million leaving a balance of $3 million of milestone-based funding to Glycotest.’

https://clinicaltrials.gov/ct2/show/NCT03878550

Updated on the 14th

Sorry, that is not from the latest report from Fuson.

Here is the link for the 2022 Semi-Annual Report. It's in Chinese but you can word search then google translate.

https://www.fosunpharma.com/Upload/File/202208/9ce59f110d1b4280825c9071414372f0.pdf

The below was published in the latest Fuson interims/annual update.

'New products such as microbial mass spectrometer (ASTA) have been launched one after another; the product pipeline includes Glycotest HCC Panel (early liver cancer diagnosis Diagnostic and screening programs), molecular POCT respiratory detection and other diagnostic products with high clinical value.'

"with associated commercialisation and sales/marketing facilities." for Glycotest this will all depend on trial success, but Proaxsis already has a growing number of products in the commercial/sales phase so, I guess this facility would be of immediate benefit for Proaxsis.

Trial dates moved out to end of 2023, which was somewhat highlighted in the last update from BOD.
As Jimzi highlighted, the US lab setup will aid Glycotest. I do worry a little on how the lab will be financed.
Watching with great interest!

All looking good here.

News from some of other investments companies is due I.e. Proaxsis.
Sofant have been quite since the order from the European space agency.

I will do a bit of digging around to see if there is anything out there on the various investments.

Good news, BOD showing some confidence in the business.

Open market buys would suggest that definitely no discounted raise on the horizon.

Nothing new but Glycotest gets a mention.

https://twitter.com/hazeldomingopa/status/1588899265023455233?s=46&t=ANoM3Mj5ccti1AhHX_UJYQ

I am personally angry with BOD for getting us in to this mess. They should have envisaged and managed financial forecast a lot better than they did.

This is snippet from a private message from GB - The Company sales growth continues with over £9m announced since the end of June and the outlook, from RNS and Interims is for a profitable year.

GB has proven himself to be an incompetent CEO.
A shameless, deceiving person.
He has zero credibility and should not hold any position in DV.

https://youtu.be/JiYk2Q36Hh0

Glycotest is still the unicorn for me. If it goes commercial, it will be very significant.

Nearly 50% of MC is covered by PDSB.

Come on NSCI, sell or float vortex bio.

PDSB finished up 14% last night.

Am I corrent in thinking EMV have aquired 16% of Ventive with no upfront cash investement?
EMV Capital has led and advised on a £2.5m investment round in domestic heat efficiency champion Ventive, and has taken a c.16% equity stake in partial settlement of fees and in line with its capital light investment model.

Am I correct in reading DVRG has until the 14 of Nov to make the interest payment?

The Company has been in talks with the Lenders for some time and it has been agreed that there will be no Event of Default relating to any repayments that have been or may be missed up to 14 November 2022 provided the balance of the principal of the funding from the Lenders and the interest to accrue until the original maturity date of 16 March 2023 is made in full immediately following the proposed equity fund raise.

Revenue is recognised at certain milestones or after project delivery and then you still have 30-90 days payment terms.

https://finance.yahoo.com/news/pds-biotech-announces-expanded-interim-120000343.html

All going good here. Impressed with how they have managed to keep a control on costs in this climate.

· 26,523 ounces ("oz") of gold produced exceeding guidance for the quarter of 23,000 - 25,000 oz
· Average ore mined grade of 4.43 grammes / tonne ("g/t")
· Senior Debt Facility tranche of US$10.3 million paid reducing Senior Debt Facility to US$28.9 million